Overview

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).

Status:
Recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Phase:

Phase 2

Details

Lead Sponsor:

AnaptysBio, Inc.